Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX4 | Q99571 | 2/20 | 0.49 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 5/20 | 0.45 |
| ▸ | MEN1 | O00255 | 5/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4821297 | 0.85 | CYP1A2 (0.55) | P2RX4P2RX7HPGDRAB9AMEN1 | |
| SCHEMBL3983979 | 0.83 | CA1 (0.55) | P2RX4P2RX7HPGDRAB9AMEN1 | |
| SCHEMBL4825991 | 0.81 | HPGD (0.49) | HPGDRAB9AMEN1KMT2AMAPT | |
| SCHEMBL4827992 | 0.81 | HPGD (0.49) | HPGDRAB9AMEN1KMT2AMAPT | |
| SCHEMBL4824928 | 0.81 | HPGD (0.49) | HPGDRAB9AMEN1KMT2AMAPT | |
| SCHEMBL15160055 | 0.81 | P2RX4 (0.49) | P2RX4P2RX7HPGDRAB9AMEN1 | |
| SCHEMBL30336705 | 0.80 | HPGD (0.70) | HPGDRAB9AMEN1KMT2AMAPT | |
| SCHEMBL14400453 | 0.80 | HPGD (0.70) | HPGDRAB9AMEN1KMT2AMAPT | |
| SCHEMBL13516845 | 0.79 | P2RX4 (0.48) | P2RX4P2RX7HPGDRAB9AMEN1 | |
| SCHEMBL17027092 | 0.79 | P2RX4 (0.51) | P2RX4P2RX7HPGDRAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7439382-B2 | 4-alkyl-2-haloaniline derivatives and process for producing the same | MEIJI SEIKA KAISHA, LTD. (JP) | 2008-10-21 | — | — | US | disclosed |
| US-20050143454-A1 | 4-Alkyl-2-haloaniline derivative and process and process for producing the same | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2005-06-30 | — | — | US | disclosed |
| EP-1506954-A1 | 4-ALKYL-2-HALOANILINE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | MEIJI SEIKA KAISHA LTD. (JP) | 2005-02-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143454-A1 | 4-Alkyl-2-haloaniline derivative and process and process for producing the same | NAT1, CYP4X1, HAX1 | P2RX4 1216/4885P2RX7 2785/4885HPGD 1153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.